Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Kindred Biosciences stock

Own Kindred Biosciences stock in just a few minutes.

Kindred Biosciences, Inc is a drug manufacturers-specialty & generic business based in the US. Kindred Biosciences shares (KIN) are listed on the NASDAQ and all prices are listed in US Dollars. Kindred Biosciences employs 63 staff and has a trailing 12-month revenue of around 0.00.

How to buy shares in Kindred Biosciences

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – KIN – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Kindred Biosciences share price

Use our graph to track the performance of KIN stocks over time.

Kindred Biosciences shares at a glance

Information last updated 2021-04-30.
52-week range$3.20 - $6.00
50-day moving average $4.85
200-day moving average $4.50
Wall St. target price$11.18
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-1.63

Buy Kindred Biosciences shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee Signup bonus
Sofi Invest
$0
Stocks, ETFs, Cryptocurrency
N/A
0%
A free way to invest in stocks, ETFs and crypto.
Robinhood
$0
Stocks, Options, ETFs
$0
0%
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Interactive Brokers
$0
Stocks, Bonds, Options, Mutual funds, ETFs, Currencies
$0 + $0.65/contract, $1 minimum
0%
N/A
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
Webull
$0
Stocks, Options, ETFs
$0
0%
Get one free stock valued between $2.50 and $250 when you open an account, one more with a deposit
Open an account
Margin financing rates start at 3.99%. No monthly subscription fees for margin.
Public
$0
Stocks, ETFs
N/A
$0 per month
N/A
loading

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Kindred Biosciences stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Kindred Biosciences financials

Revenue TTM $3.5 million
Gross profit TTM $-1,162,000
Return on assets TTM -32.42%
Return on equity TTM -29.18%
Profit margin 0%
Book value $1.71
Market capitalisation $198.5 million

TTM: trailing 12 months

Shorting Kindred Biosciences shares

There are currently 1.1 million Kindred Biosciences shares held short by investors – that's known as Kindred Biosciences's "short interest". This figure is 2.2% down from 1.1 million last month.

There are a few different ways that this level of interest in shorting Kindred Biosciences shares can be evaluated.

Kindred Biosciences's "short interest ratio" (SIR)

Kindred Biosciences's "short interest ratio" (SIR) is the quantity of Kindred Biosciences shares currently shorted divided by the average quantity of Kindred Biosciences shares traded daily (recently around 486403.03030303). Kindred Biosciences's SIR currently stands at 2.31. In other words for every 100,000 Kindred Biosciences shares traded daily on the market, roughly 2310 shares are currently held short.

However Kindred Biosciences's short interest can also be evaluated against the total number of Kindred Biosciences shares, or, against the total number of tradable Kindred Biosciences shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Kindred Biosciences's short interest could be expressed as 0.03% of the outstanding shares (for every 100,000 Kindred Biosciences shares in existence, roughly 30 shares are currently held short) or 0.0348% of the tradable shares (for every 100,000 tradable Kindred Biosciences shares, roughly 35 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Kindred Biosciences.

Find out more about how you can short Kindred Biosciences stock.

Kindred Biosciences share dividends

We're not expecting Kindred Biosciences to pay a dividend over the next 12 months.

Kindred Biosciences share price volatility

Over the last 12 months, Kindred Biosciences's shares have ranged in value from as little as $3.2 up to $6. A popular way to gauge a stock's volatility is its "beta".

KIN.US volatility(beta: 1.28)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Kindred Biosciences's is 1.2846. This would suggest that Kindred Biosciences's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Kindred Biosciences overview

Kindred Biosciences, Inc. , a commercial-stage biopharmaceutical company, engages in developing therapies for pets. Its product pipeline focuses on biologics for a range of indications primarily in dogs and cats. The company offers Mirataz, a mirtazapine transdermal ointment for the management of weight loss in cats; and Zimeta, a dipyrone injection for the control of fever in horses. It also develops KIND-016, a monoclonal antibody for the treatment of atopic dermatitis in dogs; KIND-032, a monoclonal antibody targeting interleukin-4 (IL-4) receptor for the treatment of atopic dermatitis in dogs; KIND-025 a canine fusion protein targeting IL-4 and IL-13 for atopic dermatitis in dogs; KIND-030, a monoclonal antibody targeting canine parvovirus for the prophylactic indication in dogs; KIND-509, an antibody for canine inflammatory bowel disease in dogs; KIND-510a, a long-acting feline recombinant erythropoietin being developed for the management of non-regenerative anemia in cats; and KIND-511, an anti-tumor necrosis factor treatment for newborn foals. The company was incorporated in 2012 and is headquartered in Burlingame, California. .

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site